Waning of Anti-spike Antibodies in AZD1222 (ChAdOx1) Vaccinated Healthcare Providers: A Prospective Longitudinal Study
Sanjeeb Kumar Mishra, Subrat Kumar Pradhan, Sanghamitra Pati, Sumanta Kumar Sahu, Rajiv K Nanda
Abstract
) had a higher mean titer than average or underweight persons. The only significant predictor of IgG titers at six months was SARS-CoV-2 infection on mixed model analysis. Conclusion We found a substantial decline in antibody levels leading to seven cases of seroreversion in healthcare professionals who received the ChAdOx1 vaccine. History of prior COVID-19 was the only significant factor in antibody levels at six months. Seroreversion and breakthrough infection warrant further research into the optimal timing and potential benefits of booster doses of the AZD1222 (ChAdOx1) COVID-19 vaccine.
Topics & Concepts
MedicineAntibodyVaccinationLongitudinal studyTiterProspective cohort studyInternal medicineImmunologyPediatricsPathologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesCOVID-19 epidemiological studies